Islet-Specific Tolerance Induced by T Cell Co-Receptor Therapy in Type 1 Diabetes

T 细胞辅助受体治疗在 1 型糖尿病中诱导的胰岛特异性耐受

基本信息

批准号：
8829828
负责人：
Roland M Tisch
金额：
$ 33.25万
依托单位：
UNIV OF NORTH CAROLINA CHAPEL HILL
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
起止时间：
2014-04-01 至 2019-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8829828
关键词：
Antibodies Antigen-Presenting Cells Apoptosis Apoptotic Autoimmune Diseases Autoimmunity Automobile Driving B-Lymphocytes Beta Cell Binding CD3 Antigens CD4 Antigens CD8B1 gene Cell physiology Cells Child Clinic Clinical Clinical Research Cues Cyclosporins Diabetes Mellitus Disease remission Dose-Limiting Drug toxicity Event Exhibits Fc Receptor Goals Health Human Hyperglycemia Immunotherapy In Vitro Inbred NOD Mice Individual Inflammation Insulin Insulin-Dependent Diabetes Mellitus Islet Cell Islets of Langerhans Maintenance Mediating Modeling Mus Nature Pancreas Pathology Play Property Recurrence Regulatory T-Lymphocyte Remission Induction Role Specificity T-Cell Depletion T-Lymphocyte Testing Therapeutic Time Tissues Work YARS gene crosslink diabetic diabetic patient in vivo insight insulin dependent diabetes mellitus onset islet lymph nodes mouse model novel prevent purge receptor receptor binding response trafficking type I diabetic

项目摘要

DESCRIPTION (provided by applicant): There continues to be a need for immunotherapies sufficiently robust to suppress ongoing B cell autoimmunity in type 1 diabetic individuals long-term, and reverse clinical diabetes. We found that a short course of nondepleting (ND) antibodies (Ab) specific for the T cell co-receptors CD4 and CD8 reverses diabetes in newly diabetic NOD mice, and prevents recurrent hyperglycemia indefinitely. Induction of remission by co-receptor therapy involves two key events. T cells bound by the ND aCD4 and aCD8 Ab are rapidly and selectively purged from the islets and draining pancreatic lymph nodes (PLN) due to altered trafficking properties. Secondly, TGFb1 expression is up-regulated by islet resident antigen presenting cells. On the other hand, maintenance of remission is mediated by PLN-resident Foxp3+Treg, which exhibit enhanced suppressor function. The goal of this proposal is 2-fold: 1) define the mechanisms by which co-receptor therapy induces and maintains remission in an islet/b cell-specific manner in NOD mice, and 2) extend these findings to human T effectors and FOXP3+Treg. Aim 1 focuses on how co-receptor crosslinking regulates T cell purging in a tissue-specific manner. Efforts will determine if co-receptor crosslinking similarly alters the trafficking properties of human T cells in vitro, as well as in vivo in humanized mice. Aim 2 investigates the events that promote islet- specific induction of TGFb1, and the role TGFb1 plays in diabetes remission. Finally, Aim 3 will study the direct and indirect effects of CD4 crosslinking on the properties and function of Foxp3+Treg in NOD mice. Whether co-receptor therapy also induces a distinct pool of human FOXP3+Treg with enhanced function in vivo will be tested in a humanized mouse model of islet pathology. Together this study will provide novel insight into mechanisms regulating the specificity and efficacy of ND aCD4 and aCD8 Ab treatment, in addition to better establishing the translational potential of co-receptor therapy for the treatment of human T cell-mediated pathologies.

描述（由申请人提供）：仍然需要足够鲁棒的免疫疗法来抑制长期1型糖尿病患者中持续的B细胞自身免疫性，并逆转临床糖尿病。我们发现，针对T细胞共受体CD4和CD8特异的短疗程（ND）抗体（AB）可逆转新近糖尿病的NOD小鼠中的糖尿病，并防止复发性高血糖无限期。通过共受体治疗诱导缓解涉及两个关键事件。由ND ACD4和ACD8 AB结合的T细胞因贩运性能的改变而迅速，有选择地从胰岛清除，并排出胰腺淋巴结（PLN）。其次，TGFB1表达被胰岛驻留抗原呈现细胞上调。另一方面，缓解的维持是由PLN居民Foxp3+Treg介导的，后者表现出增强的抑制功能。该提案的目的是2倍：1）定义共受体治疗在NOD小鼠中以胰岛/B细胞特异性方式诱导和保持缓解的机制，以及2）将这些发现扩展到人类T效应器和FOXP3 +treg。 AIM 1的重点是共受体交联如何以组织特异性方式调节T细胞清除。努力将确定共受体交联是否类似地改变了人类T细胞在体外的运输特性，以及人类小鼠中的体内。 AIM 2研究了促进TGFB1胰岛特异性诱导的事件，TGFB1在糖尿病缓解中的作用。最后，AIM 3将研究CD4交联对NOD小鼠Foxp3+Treg的性质和功能的直接和间接影响。共受体疗法是否还诱导了具有增强体内功能增强的人类Foxp3+Treg的独特库，将在人源化的小鼠胰岛病理模型中进行测试。这项研究将共同提供对调节ND ACD4和ACD8 AB治疗的特异性和功效的机制的新见解，此外还可以更好地确定共受体治疗的转化潜力来治疗人T细胞介导的病理学。